QR kód

First Documented Response to Tarlatamab in a Patient With Transformed SCLC Without Actionable Gene Alteration: Case Report

Tarlatamab, a DLL3-targeting bispecific T-cell engager, has exhibited substantial survival benefits in relapsed and refractory extensive-stage SCLC. Its efficacy in transformed SCLC, however, particularly in patients without actionable genetic alterations (AGA), remains largely unknown. Histologic t...

Celý popis

Uloženo v:
Hlavní autoři: Brandon Poppe, DO, Taylor Praska, PharmD, Monica Camou, FNP, Amanda Edmond, PA-C, Jiaxin Niu, MD, PhD
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2026-05-01
Edice:JTO Clinical and Research Reports
Témata:
Tarlatamab
SCLC
Transformation
Case report
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2666364326000068
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky